Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human Trial of the Safety and Performance of NU-MAX® (IEIK13) as a Hemostatic Agent in Intracranial Neurosurgery

NCT04953949 is registered in ClinicalTrials.gov with 3-D Matrix Europe SAS as lead sponsor.

NCT NCT04953949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04953949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human Trial of the Safety and Performance of NU-MAX® (IEIK13) as a Hemostatic Agent in Intracranial Neurosurgery
Lead sponsor
3-D Matrix Europe SAS
Phase
Not applicable
Overall status
Completed
Start date
August 6, 2021
Completion date
November 4, 2023
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oozing (hemorrhage) during intracranial procedures